More Articles

Medicines for Europe 2nd Value Added Medicines Conference 2018 Conferences | Posted 06/07/2018

Medicines for Europe 2nd Value Added Medicines Conference 2018 21 November 2018 Renaissance Hotel, BrusselsBelgium

SMi 5th Annual Biosimilars USA Conference 2018 Conferences | Posted 06/07/2018

SMi 5th Annual Biosimilars USA Conference 2018 14–15 November 2018 Renaissance Woodbridge Hotel, IselinNew Jersey, USA

Biosimilars development moving to Asia Reports | Posted 29/06/2018

Biosimilars manufacturing is moving to Asia with biosimilars developed in Korea contributing 43% of the global biosimilars value. This has been a quick expansion from the total share of 0% back in...

FDA rejects Amgen’s trastuzumab biosimilar Biosimilars/News | Posted 29/06/2018

Biotech giant Amgen announced on 4 June 2018 that the US Food and Drug Administration (FDA) had rejected the application for approval of its trastuzumab biosimilar.

Biosimilar insulins have same efficacy and safety as reference biologicals Biosimilars/Research | Posted 29/06/2018

Researchers from the US have found that biosimilar insulins have comparable safety and clinical efficacy as their reference biologicals [1].

Biosimilar infliximab blocked in Australia Biosimilars/General | Posted 29/06/2018

Switzerland-based drug giant F. Hoffmann-La Roche (Roche) has gained a temporary order in an Australian Federal Court blocking Sandoz from launching its rituximab biosimilar.

Savings with use of biosimilar trastuzumab for breast cancer patients in Croatia Biosimilars/Research | Posted 29/06/2018

Breast cancer is worldwide the most common cancer in women. In 2012 alone, there were approximately 464,000 new cases and 131,000 deaths from breast cancer in Europe. In Croatia, breast cancer was...

Generic clopidogrel non-inferior to Plavix in acute coronary syndrome Generics/Research | Posted 29/06/2018

A team of Canadian researchers have concluded that generic clopidogrel is non-inferior to the originator drug, Plavix (clopidogrel), in the treatment of patients with acute coronary syndrome [1]